Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi : Impact Factor & More
pISSN: 0253-2727
Share this on:
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi Journal Specifications
Indexed in the following public directories
Scopus 
SJR
| Overview | |
| Publisher | Zhongguo Yixue Kexueyuan |
Planning to publish in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Variables associated with severe cytopenia in adult chronic phase chronic myeloid leukemia patients receiving initial tyrosine kinase inhibitors
- 14 Mar 2026
- Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Treatment practice and outcomes in 125 patients with autoimmune hemolytic anemia: a single-center retrospective analysis
- 14 Mar 2026
- Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Niemann-Pick disease with two missense mutations in SMPD1 gene: a case report and literature review
- 14 Mar 2026
- Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
A single-center study on the clinical characteristics of 15 cases of large granular lymphocytic leukemia
- 14 Mar 2026
- Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Caplacizumab combined with therapeutic plasma exchange, glucocorticoids, and rituximab for refractory thrombotic thrombocytopenic purpura: a case report and literature review
- 14 Mar 2026
- Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Comparison of the efficacy and safety of venetoclax plus azacitidine versus D-CAG regimen in the treatment of elderly patients with relapsed or refractory acute myeloid leukemia
- 14 Mar 2026
- Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Variables associated with severe cytopenia in adult chronic phase chronic myeloid leukemia patients receiving initial tyrosine kinase inhibitors
- 14 Mar 2026
- Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Treatment practice and outcomes in 125 patients with autoimmune hemolytic anemia: a single-center retrospective analysis
- 14 Mar 2026
- Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Niemann-Pick disease with two missense mutations in SMPD1 gene: a case report and literature review
- 14 Mar 2026
- Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
A single-center study on the clinical characteristics of 15 cases of large granular lymphocytic leukemia
- 14 Mar 2026
- Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Caplacizumab combined with therapeutic plasma exchange, glucocorticoids, and rituximab for refractory thrombotic thrombocytopenic purpura: a case report and literature review
- 14 Mar 2026
- Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Comparison of the efficacy and safety of venetoclax plus azacitidine versus D-CAG regimen in the treatment of elderly patients with relapsed or refractory acute myeloid leukemia
- 14 Mar 2026
- Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
FAQs on Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
How many articles did Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi publish last year? 
Who is the publisher of Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi?
